Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1995 - Detectability of RET fusions by amplicon-based next generation sequencing in nationwide lung cancer genomic screening project : LC-SCRUM-Japan

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Targeted Therapy;  Non-Small Cell Lung Cancer

Presenters

Yuko Usui

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

Y. Usui1, K. Kirita1, S. Matsumoto1, Y. Ohe2, M. Nishio3, T. Seto4, M. Kodani5, K. Taima6, Y. Hattori7, T. Kohno8, K. Yoh1, K. Goto1

Author affiliations

  • 1 Thoracic Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Department Of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 4 Department Of Thoracic Oncology, National Kyushu Cancer Center, 811-1395 - FUKUOKA/JP
  • 5 3rd Internal Medicine, Tottori University Hospital, 683-8504 - Yonago/JP
  • 6 Department Of Respiratory Medicine, Hirosaki University, 036-8562 - Hirosaki/JP
  • 7 Department Of Thoracic Oncology, Hyogo Cancer Center, Akashi/JP
  • 8 Research Institute, National Cancer Center, 104-0045 - Tokyo/JP
More

Resources

Abstract 1995

Background

RET fusions have been identified as a therapeutic target in non-small cell lung cancer (NSCLC). The establishment of molecular diagnostics for RET fusions is required for the development of molecular-targeted therapies for fusion-positive patients. We have operated molecular testing for various actionable gene alterations, including RET fusions, in our nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan).

Methods

Since 2013, RET fusions were analyzed by multiplex RT-PCR, and fusion-positive samples were confirmed by break-apart FISH. Since 2015, an amplicon-based next generation sequencing (NGS) system, Oncomine™ Comprehensive Assay was also applied in our genomic screening.

Results

As of February 2017, 244 institutions across Japan were participating, and a total of 4015 lung cancer patients including 3392 non-squamous (Non-Sq) NSCLCs were enrolled into the LC-SCRUM-Japan. Of the Non-Sq NSCLCs, available samples for multiplex RT-PCR and NGS were 94% (3186/3392) and 90% (1671/1852), respectively. RET fusions were detected in 89 samples (2.8%), including 54 detected by NGS. The types of variants found were KIF5B-RET (n = 50, 56%), CCDC6-RET (n = 20, 22%) and undetermined (n = 19, 21%). Of the 54 RET fusion-positive samples by NGS, the positivity was confirmed using break-apart FISH in 35 (92%) of 38 available samples. Among the 1335 samples available for both RT-PCR and NGS, the concordance rate between the two assays for the detection of RET fusions were 0.99. The detection sensitivity and specificity of the fusions in NGS assay were 0.98 and 0.99.

Conclusions

Our nation-wide screening results revealed that this amplicon-based NGS assay showed high sensitivity and specificity for the detection of RET fusions and is clinically applicable for diagnosis of RET fusions in lung cancer.

Clinical trial identification

Legal entity responsible for the study

National Cancer Center

Funding

Astra Zeneka, Eisai, Chugai Pharmaceutical, Pfizer, DAIICHI SANKYO, Astellas Pharma, Taiho Pharmaceutical, Ono Pharmaceutical, Kyowa Hakko Kirin, Eli Lilly Japan, Takeda Pharmaceutical, Novartis Pharma, Amgen Astellas BioPharma, MSD, Merck Serono.

Disclosure

S. Matsumoto: Astra Zeneka, Eisai, Chugai Pharmaceutical, Pfizer, Daiichi Sankyo, Astellas Pharma, Taiho Pharmaceutical, Ono Pharmaceutical, Kyowa Hakko Kirin, Eli Lilly Japan, Takeda Pharmaceutical, Novartis Pharma, Amgen Astellas BioPharma, MSD, Merck Serono. Y. Ohe: Honorarium/Consultant/Expert Testimony/Research Funding (Institution); AstraZeneca, Chugai, Lilly, ONO, BMS, Daiichi-Sankyo, Nipponkayaku, Boehringer, Bayer, Pfizer, MSD, Taiho, Clovis, Sanofi, Novartis, Kyorin, Dainippon-Sumitomo, Merck. M. Nishio: Novartis, Ono Pharmaceutical, Bristol-Myers Squibb, TAIHO Pharmaceutical, Eli Lilly, Pfizer, Astellas Pharma, AstraZeneca and Honoraria, Pfizer, Bristol-Myers Squibb, Chugai Pharmaceutical, Taiho Pharmaceutical, AstraZeneca. T. Seto: AstraZeneca, Astellas Pharma, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Merck Serono, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Bristol-Myers Squibb, Kissei, Kyowa Hakko Kirin, Nippon Kayaku, Ono, Roche Singapore Pte, Taiho, Yakult. K. Yoh: AstraZeneca, Chugai Pharma, Boehringer Ingelheim, Lilly Japan, Bristol-Myers Squibb, Taiho Pharmaceutical, Ono Pharmaceutical, Pfizer. K. Goto: Astellas Pharma, Astra Zeneka, Amgen Astellas BioPharma, Eisai, Ono, Kyowa Hakko Kirin, Daiichi Sankyo, Taiho, Takeda, Chugai, Novartis, Pfizer, MSD, Eli Lilly, Merck Serono, Bristol-Myers Squibb, Life Technologies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.